Researchers found an ancient Chinese herbal remedy can ease the side effects of chemotherapy
By Tara Foss
WebMD Health News
Reviewed by Dr Farah Ahmed
19th August - A new study suggests that an 1,800-year-old Chinese herbal remedy may reduce the unpleasant gastrointestinal side effects of chemotherapy. The research was funded by the National Cancer Institute and the National Institutes of Health in the US, and appears in Science Translational Medicine....
Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
ROME, August 19, 2010 /PRNewswire/ -- Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results...
(Nanowerk News) With a single breath, a Breathalyzer™ can tell a police officer when a driver has had too much to drink. Now, thanks to a team of investigators at the Israel Institute of Technology, a single breath may be enough to tell a doctor that their patient has cancer.
Reporting its work in the British Journal of Cancer ("Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors"),...
Neogenix Oncology Receives Patent for DNAs Encoding Its NPC-1 Antibody, Further Expanding Patent Portfolio
GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 7,763,720, with claims related to DNAs encoding the novel molecular aspects of the Company’s NPC-1 antibody.
“This additional patent further enhances the Company’s growing library of varied patents of different aspects...
Second-Generation Cancer Drug Targeting Patients' Specific Molecular Defects Is Showing Encouraging Results In Early Clinical Trials
A second-generation cancer drug that targets patients' specific molecular defects is showing encouraging results in early clinical trials, according to a study published in the latest edition of the Journal of Clinical Oncology.
Researchers from the Drug Development Unit at The Institute of Cancer Research (ICR) and The Royal Marsden NHS...
